Connect your AI

Anika Therapeutics ANIK Price / sales

Price / sales at other companies

StrykerSYK

5×-1.1×

VericelVCEL

5.6×-3.8×

Zimmer Biomet HoldingsZBH

2.1×-0.8×

Pacira BioSciences, Inc.PCRX

1.2×-0.4×

BioventusBVS

1.1×0.0×

Xtant Medical HoldingsXTNT

0.6×+0.1×

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

market cap/total revenue=1.7×

Based on the most recent quarter.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's price / sales?: Anika Therapeutics (ANIK) reported price / sales of 1.7× in Q1 2026.
How has Anika Therapeutics's price / sales changed year-over-year?: Anika Therapeutics's price / sales decreased by 16.2% year-over-year, from 2× to 1.7×.
What is the long-term trend for Anika Therapeutics's price / sales?: Over 5 years (2020 to 2025), Anika Therapeutics's price / sales has grown at a -24.5% compound annual growth rate (CAGR), from 5× to 1.2×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.